Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis

Joint Bone Spine

Volumn 79, Issue 6, 2012, Pages 621-623

  Moltó, Anna ^a,c   Ea, Hang Korng ^a,b,c   Richette, Pascal ^a,b,c   Bardin, Thomas ^a,b,c   Lioté, Frédéric ^a,b,c  

^a CENTRE VIGGO PETERSEN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

Author keywords

Anakinra; Calcium pyrophosphate cristal; Interleukin 1; Refractory arthritis; Treatment

Indexed keywords

C REACTIVE PROTEIN; CALCIUM PYROPHOSPHATE; COLCHICINE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID;

ADOLESCENT; ADULT; ARTHRITIS; ARTICLE; CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; INJECTION SITE REACTION; MALE; PAIN ASSESSMENT; POLYARTHRITIS; PROTEIN BLOOD LEVEL; SYSTEMIC THERAPY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS; C-REACTIVE PROTEIN; CALCIUM PYROPHOSPHATE; CRYSTALLIZATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; PAIN MEASUREMENT; RECEPTORS, INTERLEUKIN-1; TREATMENT OUTCOME;

EID: 84870699350     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.01.010     Document Type: Article

References (14)

1. Richette P., Bardin T., Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford) 2009, 48:711-715.
2. Martinon F., Petrilli V., Mayor A., et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
3. So A., De Meulemeester M., Pikhlak A., et al. Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 2010, 62:3064-3076.
4. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
5. Terkeltaub R., Sundy J.S., Schumacher H.R., et al. The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study. Ann Rheum Dis 2009, 68:1613-1617.
6. Announ N., Palmer G., Guerne P.-A., et al. Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine 2009, 76:424-426.
7. McGonagle D., Tan A.L., Madden J., et al. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum 2008, 58:631-633.
8. Dinarello C.A. Blocking interleukin-1beta in acute and chronic auto-inflammatory diseases. J Intern Med 2011, 269:16-28.
9. Zhang W., Doherty M., Bardin T., et al. EULAR recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011, 70:563-570.
10. Zhang W., Doherty M., Pascual E., et al. EULAR recommendations for calcium pyrophosphate deposition. Part II: management. Ann Rheum Dis 2011, 70:571-575.
11. Molto A., Olivé A. Anti-IL-1 molecules: new comers and new indications. Joint Bone Spine 2010, 77:102-107.
12. Chen K., Fields T., Mancuso C.A., et al. Anakinra's efficacy is variable in refractory gout: report of ten cases. Semin Arthritis Rheum 2010, 40:210-214.
13. Schlesinger N., Mysler E., Lin H.Y., et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011, 70:1264-1271.
14. Khanna D., Sarkin A.J., Khanna P.P., et al. Minimally important differences of the gout impact scale in a randomized controlled trial. Rheumatology (Oxford) 2011, 50:1331-1336.